Kurv Yield Premium Strategy Tesla (TSLA) ETF (TSLP)
BATS: TSLP · IEX Real-Time Price · USD
19.90
-0.24 (-1.20%)
May 20, 2024, 10:07 AM EDT - Market open
-1.20% (1D)
| Assets | $2.18M |
| Expense Ratio | 0.99% |
| PE Ratio | n/a |
| Shares Out | 100,000 |
| Dividend (ttm) | $3.06 |
| Dividend Yield | 15.35% |
| Ex-Dividend Date | Apr 24, 2024 |
| Payout Ratio | n/a |
| 1-Year Return | n/a |
| Volume | 2,892 |
| Open | 19.93 |
| Previous Close | 20.14 |
| Day's Range | 19.85 - 20.23 |
| 52-Week Low | 16.17 |
| 52-Week High | 29.89 |
| Beta | n/a |
| Holdings | 10 |
| Inception Date | Oct 27, 2023 |
About TSLP
Fund Home PageThe Kurv Yield Premium Strategy Tesla (TSLA) ETF (TSLP) is an exchange-traded fund that mostly invests in consumer discretionary equity. The fund seeks to provide current income and capped gains on the Tesla stock (TSLA) through a synthetic covered call strategy, collateralized by cash and short-term fixed-income instruments. The actively managed fund uses both standardized exchange-traded and FLEX options. TSLP was launched on Oct 27, 2023 and is issued by Kurv.
Asset Class Equity
Category Large Blend
Region North America
Stock Exchange BATS
Ticker Symbol TSLP
ETF Provider Kurv
Top 10 Holdings
100.00% of assets| Name | Symbol | Weight |
|---|---|---|
| United States Treasury Bills 0% | B 0 07.11.24 | 52.80% |
| United States Treasury Bills 0% | B 0 06.27.24 | 27.73% |
| United States Treasury Bills 0% | B 0 06.11.24 | 23.05% |
| Tsla 07/19/2024 190 C | n/a | 12.33% |
| Cash Offset | n/a | 8.36% |
| Northern Funds - U.S. Government Money Market Fund | NOGXX | 3.67% |
| US DOLLARS | n/a | 0.80% |
| DEPOSITS WITH BROKER FOR SHORT POSITIONS | n/a | -0.03% |
| Tsla 06/21/2024 215 C | n/a | -2.52% |
| Tsla 07/19/2024 190 P | n/a | -26.20% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Apr 24, 2024 | $0.4239 | Apr 26, 2024 |
| Mar 20, 2024 | $0.5189 | Mar 22, 2024 |
| Feb 21, 2024 | $0.313 | Feb 23, 2024 |
| Jan 24, 2024 | $0.5555 | Jan 26, 2024 |
| Dec 20, 2023 | $0.6664 | Dec 22, 2023 |
| Nov 22, 2023 | $0.5775 | Nov 27, 2023 |
News
AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Soci...
Other symbols: AZN
19 days ago - Business Wire